The International Society for Pharmacoeconomics and Outcomes Research’s Value in Health interviewed Optum Chief Medical Officer Brian Solow and Enlightenment Bioconsult LLC CEO Edmund Pezalla about the use of cost effectiveness decision making among insurers in the U.S.
The interview was part of ISPOR’s Special Task Force Report on value assessment frameworks.
“A lot of plans look at cost effectiveness and they use it to project what they might want to do if they’re signing an outcomes-based contract or if they’re actively trying to promote one treatment over another,” Pezalla says. “But most insurers don’t have formal policies allowing them to use cost-effectiveness research in decision making.”
To read the full article in Value in Health, click here.